Compare · ABVX vs NVO
ABVX vs NVO
Side-by-side comparison of Abivax SA (ABVX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABVX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 20.3x ABVX ($9.07B).
- Over the past year, ABVX is up 1496.1% and NVO is down 34.2% - ABVX leads by 1530.3 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for ABVX).
- NVO has more recent analyst coverage (25 ratings vs 14 for ABVX).
- Company
- Abivax SA
- Novo Nordisk A/S
- Price
- $114.52+1.09%
- $41.18+6.93%
- Market cap
- $9.07B
- $183.82B
- 1M return
- +3.22%
- +13.32%
- 1Y return
- +1496.10%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 3
- 5
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABVX
- Abivax to Present Data on Obefazimod at Digestive Disease Week®
- SEC Form 6-K filed by Abivax SA
- Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
- Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
- SEC Form S-8 filed by Abivax SA
- SEC Form 20-F filed by Abivax SA
- SEC Form 6-K filed by Abivax SA
- Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
- Jefferies initiated coverage on Abivax SA with a new price target
- Wedbush initiated coverage on Abivax SA with a new price target
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S